Iranian Journal of Diabetes and Obesity
Shahid Sadoughi University Of Medical Sciences
Thu, Jul 31, 2025
[Archive]
Volume 17, Issue 3 (7-2025)
IJDO 2025, 17(3): 193-197 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Babaee H, Mobini M, Niksolat F, Hoseinian Amiri A, Ali Mohammadpour R. Determining the Frequency of Metabolic Syndrome in Gout Patients in Rheumatology Clinics of Sari in 2023-24. IJDO 2025; 17 (3) :193-197
URL: http://ijdo.ssu.ac.ir/article-1-968-en.html
URL: http://ijdo.ssu.ac.ir/article-1-968-en.html
Professor, Department of Internal Medicine, Diabetes Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
Abstract: (24 Views)
Objective: Gout and metabolic syndrome (MetS) are associated with increased risk of cardiovascular involvement. The aim of the current study was to evaluate the frequency of MetS and its components in patients with gout.
Materials and Methods: This cross-sectional study was conducted on 150 patients with gout in Sari, Iran. The demographic, clinical and laboratory variables of the patients were recorded. The MetS was defined by the 2005 National Cholesterol Education Program (NCEP/ATP III) and International Diabetes Federation (IDF). Then, patients with gout with and without metabolic syndrome were compared in terms of demographic and clinical characteristics. Data analysis was performed by SPSS (version 19), at a significance level of < 0.05.
Results: The mean age of the patients was 50.17±15 year. Based on the NCEP/ATP III and IDF criteria, 88 (58.7%) and 90 (60%) were diagnosed with MetS, respectively. Age, body mass index, and duration of gout were significantly higher in patients with MetS criteria (P< 0.05).
Conclusion: The frequency of MetS was found about 60% of patients with gout. Hypertriglyceridemia and central obesity are two more prevalent components of MetS in our patients. The association of MetS and cardiovascular diseases highlights the importance of attention and management of this condition in patients with gout.
Materials and Methods: This cross-sectional study was conducted on 150 patients with gout in Sari, Iran. The demographic, clinical and laboratory variables of the patients were recorded. The MetS was defined by the 2005 National Cholesterol Education Program (NCEP/ATP III) and International Diabetes Federation (IDF). Then, patients with gout with and without metabolic syndrome were compared in terms of demographic and clinical characteristics. Data analysis was performed by SPSS (version 19), at a significance level of < 0.05.
Results: The mean age of the patients was 50.17±15 year. Based on the NCEP/ATP III and IDF criteria, 88 (58.7%) and 90 (60%) were diagnosed with MetS, respectively. Age, body mass index, and duration of gout were significantly higher in patients with MetS criteria (P< 0.05).
Conclusion: The frequency of MetS was found about 60% of patients with gout. Hypertriglyceridemia and central obesity are two more prevalent components of MetS in our patients. The association of MetS and cardiovascular diseases highlights the importance of attention and management of this condition in patients with gout.
Type of Study: Research |
Subject:
Special
Received: 2025/01/29 | Accepted: 2025/06/11 | Published: 2025/07/28
Received: 2025/01/29 | Accepted: 2025/06/11 | Published: 2025/07/28
References
1. Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nature Reviews Rheumatology. 2022;18(2):97-111.
2. Davatchi F, Sandoughi M, Moghimi N, Jamshidi AR, Tehrani Banihashemi A, Zakeri Z, et al. Epidemiology of rheumatic diseases in Iran from analysis of four COPCORD studies. International journal of rheumatic diseases. 2016;19(11):1056-62.
3. Targher G, Bertolini L, Tessari R, Zenari L, Arcaro G. The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients. The Valpolicella Heart Diabetes Study. Diabetic medicine. 2006;23(11):1270-1.
4. Detection NE. Evaluation. AND Treatment OF High Blood Cholesterol IN Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP)(Adult treatment Panel III) JAMA. 2001:2486-97.
5. Ebrahimi H, Emamian MH, Shariati M, Hashemi H, Fotouhi A. Metabolic syndrome and its risk factors among middle aged population of Iran, a population based study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2016;10(1):19-22.
6. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Care & Research: Official Journal of the American College of Rheumatology. 2007;57(1):109-15. [DOI:10.1002/art.22466]
7. Jung JH, Song GG, Ji JD, Lee YH, Kim JH, Seo YH, et al. Metabolic syndrome: prevalence and risk factors in Korean gout patients. The Korean journal of internal medicine. 2016;33(4):815.
8. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. The American journal of medicine. 2012;125(7):679-87.
9. Rafieian-Kopaei M, Behradmanesh S, Kheiri S, Nasri H. Association of serum uric acid with level of blood pressure in type 2 diabetic patients. Iran J Kidney Dis, 2014. 8(2): p. 152-4.
10. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Current opinion in rheumatology. 2013;25(2):210-6.
11. Peláez-Ballestas I, Cuevas CH, Burgos-Vargas R, Roque LH, Terán L, Espinoza J, et al. Diagnosis of chronic gout: evaluating the American College of Rheumatology proposal, European League Against Rheumatism recommendations, and clinical judgment. The Journal of rheumatology. 2010;37(8):1743-8.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
